跳转至内容
Merck
CN

L4795

Sigma-Aldrich

L-365260

≥98% (HPLC)

别名:

N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N′-(3-methylphenyl)-urea

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C24H22N4O2
分子量:
398.46
UNSPSC代码:
12352202
PubChem化学物质编号:
NACRES:
NA.77

检测方案

≥98% (HPLC)

形式

solid

药品控制

regulated under CDSA - not available from Sigma-Aldrich Canada

储存条件

desiccated

溶解性

DMSO: >20 mg/mL

创始人

Merck & Co., Inc., Kenilworth, NJ, U.S.

储存温度

−20°C

SMILES字符串

CN1C[C@H](NC(=O)Nc2cccc(C)c2)N=C(c3ccccc3)c4ccccc14

InChI

1S/C24H24N4O/c1-17-9-8-12-19(15-17)25-24(29)27-22-16-28(2)21-14-7-6-13-20(21)23(26-22)18-10-4-3-5-11-18/h3-15,22H,16H2,1-2H3,(H2,25,27,29)/t22-/m0/s1

InChI key

LIVVMCBMGZZRRY-QFIPXVFZSA-N

生化/生理作用

L-365260 is a CCK2 selective antagonist. Enhances amphetamine-induced stimulation of locomotor activity in rats (a model of drug abuse), inhibits thyroid carcinoma (TT)-cell proliferation (potential therapeutic implication for cancer treatment); bilateral injection into the medulla reverses both tactile allodynia and thermal hyperalgesia.

特点和优势

This compound is featured on the Cholecystokinin and Gastrin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Skull and crossbonesEnvironment

警示用语:

Danger

危险声明

危险分类

Acute Tox. 3 Oral - Aquatic Acute 1

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Kristiina Roots et al.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience, 24(6), 395-400 (2006-07-11)
This study provides the first evidence that CCK-8 (0.01 pM to 0.1 mM) stimulates Na,K-ATPase in the cortical membranes of wild-type and CCK(2) receptor-deficient mice. In each genotype, the maximal stimulation was about 40%. Homozygous mice revealed substantially lower EC50
Jun Cao et al.
Zhonghua yi xue za zhi, 87(24), 1704-1708 (2007-09-11)
To explore the molecular mechanism of increasing the invasion of colon cancer cells by gastrin 17. The plasmid pCR 3.1/GR expressing the gastrin receptor cholecystokinin-2 receptor (CCK-2R) was transfected into colonic carcinoma cells of the line Colo320 by Lipofectamine 2000.
Dan Li et al.
Ai zheng = Aizheng = Chinese journal of cancer, 27(1), 41-45 (2008-01-11)
Gastrin contributes to the growth and proliferation of gastric cancer cells and it is related to the effect of tyrosine kinase. This study was to investigate the effect of gastrin on tyrosine phosphorylation of focal adhesion kinase (FAK) in human
Jennifer M Mitchell et al.
Pharmacology, biochemistry, and behavior, 85(4), 787-795 (2007-01-02)
There is evidence that the neuropeptide cholecystokinin (CCK) is important for the rewarding effects of drugs of abuse. However, less is known regarding the role of CCK in drug seeking and craving. The present study investigated whether the CCK(B) antagonist
Mei Ming et al.
Zhonghua zhong liu za zhi [Chinese journal of oncology], 29(1), 4-8 (2007-06-20)
To study the effect of gastrin on the mRNA and protein expression of urokinase-type plasminogen activator (u-PA) in human colon cancer cells and detect the role of p38 MAPK in this process. Lipofectin method was used to transfect pCR3. 1/CCK2R

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门